This week’s collection of the latest dermatologic studies covers the connection between dermatology and COVID-19, the efficacy of topical 5-fluorouracil and imiquimod in treating cutaneous squamous cell carcinoma in situ, challenges in treating chronic spontaneous urticaria, and patient satisfaction of treating recalcitrant keloids with intralesional bleomycin and lidocaine.
The botanical blend also demonstrated potential to protect the skin from free radical damage on a cellular level, the study found.
The study will evaluate rezpegaldesleukin and its effect on Severity of Alopecia Tool scoring by the conclusion of a 36-week period.
Nitin Joshi, PhD, shared CAGE Bio’s development of CGB-500 and why phase 2 EASI scores have the company’s scientific advisory board optimistic.
The approval also marks the first and only approved HA dermal filler approved in the US for use in the upper face.
It is always essential to have clear communication regarding expectations at your new practice.
Factors including disease duration, treatment response, and mental health were listed as crucial factors in severity and treatment.
Test your knowledge on the AAD's recommendations for phototherapy, monoclonal antibodies, JAK inhibitors, and systemic therapies in the latest guidelines.
As someone who practices dermatology, it can often be difficult to determine if any of these new skin care trends are efficacious.
We want to know: Will you be attending the conference in San Diego later this week?
Raj Chovatiya, MD, PhD, gives a sneak peek of what to expect in atopic dermatitis education at the 2024 American Academy of Dermatology (AAD) Meeting in San Diego, California March 8-12. Since the last meeting, the AAD has released new guidelines to treat the condition.
Psoriasis is linked to a heightened risk of cardiovascular disease, necessitating proactive screening, collaborative care, and consideration of potential impacts of psoriasis treatments on cardiovascular health.
Keep up with the latest headlines in dermatology from the past week, including a physician working to address the overlooked issue of skin diseases in Black patients, the initiation of a Good Laboratory Practice toxicology study for topical treatment DB-007-4, and more.
ICYMI, this week we had news about late-breaking phase 2 data on rilzabrutinib for CSU, data from the BRAVE-AA1 and BRAVE-AA2 trials for alopecia areata, Rare Disease Day insights, and more.
In this week’s Pointers With Portela, the 208SkinDoc discusses dangerous skin care marketing to watch out for.
In most kidney transplant recipients with advanced skin cancer, 2 checkpoint inhibitors are needed to boost the immune system, according to a new study.
Despite its black box warning, isotretinoin does not appear to increase the risk of suicide in acne patients, a finding investigators say is reassuring in their latest research.
The EACH one TEACH one program aims to enhance access to dermatologic care for residents of southeast Washington, DC, Wards 7 and 8.
Dermatology Times asked our readers to share what conferences they are looking forward to in the first quarter of 2024.
Learn more about the in-depth topics covered in the February 2024 print issue of Dermatology Times.
Dermatology Times is looking back on the top stories in dermatology from the month of February.
Click here to answer our poll on rare dermatologic diseases.
Today is Rare Disease Day. Here's a look back at news related to rare skin conditions over the past year.
As a pharmacy benefit manager, Livinti will help reduce biologic drug costs for self-funded employees.
This Rare Disease Day, Joseph Zabinski, PhD, MEM, of OM1, discusses the role of artificial intelligence in helping to detect rare dermatologic diseases.
The collaboration with Sato marks a continued effort of Arcutis to collaborate with pharmaceutical companies and license topical roflumilast in Asia.
This Rare Disease Day, Stefan Weiss, MD, MBA, FAAD, of OM1, shares his expertise in AI’s capabilities in dermatology.
Review Dermatology Times’ February content uplifting Black voices.
Timely systemic treatment of atopic dermatitis—before visible lesions appear—may help halt the atopic march into allergies and asthma.
Susan Taylor, MD, believes in training more investigators that serve diverse populations to enhance clinical trials. Here are a few resources to get started in clinical trials.
